AB Science announced today that the Canadian health authority (Health Canada) has issued a preliminary review acceptance letter for the registration file for masitinib in the treatment of amyotrophic lateral sclerosis (ALS).

The company explains that this means that the information and documents submitted by AB Science in response to the Notice of Deficiency (NOD) previously issued by Health Canada have been reviewed and deemed acceptable to resume the evaluation of the file.

' This notice from the agency is an important step in the procedure, and marks the effective date for Health Canada to resume its review of the file. Indeed, when the response to the NOD is examined and deemed acceptable for scientific review, a new review period begins immediately", says the company.

Health Canada has a maximum of 200 calendar days to examine the file.

Copyright (c) 2023 CercleFinance.com. All rights reserved.